|A new Drug Development and Pharmacogenomics Academy at Emory University will offer a year-long lineup of nationally recognized basic scientists, clinical researchers and biostatisticians presenting an A to Z view of the drug pipeline and steps involved in discovering and developing effective pharmaceuticals.
The free educational program, called "A 3-D Look at Cancer Drugs: From Discovery to Development to Delivery," is sponsored by Emory's Winship Cancer Institute and the Department of Pharmacology in Emory University School of Medicine.
The inaugural lecture on Monday, August 30 features Thomas Roberts, PhD, faculty dean of the Division of Medical Sciences, professor and chair of the Department of Cancer Biology at Harvard Medical School, speaking on "Kinase Inhibitors in Cancer Therapy and Research." Dr. Roberts is considered one of the fathers of kinase therapy, the research that led to the development of breakthrough drugs such as Gleevec for chronic myelogenous leukemia. The program begins with a reception at 4:00 pm in the 5th floor conference room of the Winship Cancer Institute on the Emory campus. Dr. Roberts' presentation will be followed by a dinner on the plaza level of the Woodruff Health Sciences Center Administration Building.
The ongoing Academy schedule includes twice-monthly programs on Thursdays, beginning at 5:30 pm with a light meal, followed by a lecture and round table discussion at 6:00 pm. Lectures and discussions, delivered by leading scientists and clinicians from throughout the country, will focus on drug discovery and preclinical development; clinical drug development; and regulatory approval and public policy. The presenters will share their perspectives on how the cancer community can delineate better strategies for new drug discovery; create better clinical trial designs for improved drug development; and increase understanding of how to implement better clinical practice for patient care.
Emory invites the local scientific and medical community to the seminar series, including medical fellows and trainees; basic science post-doctoral fellows and graduate students; faculty and research staff at area universities, research institutions, hospitals, and pharma/biotech companies; and community physicians.
"This Drug Development and Pharmacogenomics Academy will cover all aspects of drug development, from concept to high throughput assays all the way through preclinical and clinical development of compounds, including pitfalls and tricks of the trade," said Fadlo R. Khuri, MD, co-director of the Academy, chief medical officer of the Winship Cancer Institute and associate director of Clinical and Translational Cancer Research. "Our faculty lecturers will cover a broad spectrum of science and medicine, from academia, industry, clinical medicine and government." Haian Fu, PhD, associate professor of pharmacology at Emory University School of Medicine and Director of the Emory Chemistry-Biology Center for Drug Discovery, will co-direct the course.
More information about the Academy and a registration form are available at the Winship Cancer Institute website: http://www.winshipcancerinstitute.org.CME credit is available for individual seminars or the entire course of lectures.
The Winship Cancer Institute appreciates the support of Aventis, which provided a major, unrestricted grant for the Academy.